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Background
Can the same brand name drug contain a
different active ingredient in a different country?
The answer to this question is, unfortunately, yes.
With the growing trend in drug reimportation
from other countries, differences in actual drug
content are being discovered for the same brand
name. With increased travel to countries outside
the US and Canada, greater and lengthened
military service in foreign countries, and
expanded use of the internet for less expensive
prescription drugs, the possibility of acquiring a
brand name drug with an unexpected active
ingredient is increasing.
The Institute for Safe Medication Practices
(ISMP) recently reported that a patient taking
Dilacor XR (diltiazem extended release) 120 mg
daily for hypertension received a different product
with the same name while traveling in Serbia.
This patient ran out of the US prescribed product
and obtained Dilacor from a Serbian pharmacy.
The pharmacist filled the prescription with the
Serbian Dilacor brand which is digoxin. The
patient did not notice the difference in product
strength or appearance and continued to take the
Serbian Dilacor. Because the patient felt that his
hypertension was not being controlled, he elected
to take extra daily doses. Three days later, he
developed signs of digoxin toxicity, was admitted
to an emergency facility, and treated with
Digibind (digoxin immune FAB).1
Dilacor is also the brand name for the
antihypertensive agents barnidipine in Argentina
and verapamil in Brazil.2

Commentary
This is one example of the same brand name
being used by different manufacturers for
different drugs in other countries. There are
several other examples. Flomax (tamsulosin) for
benign prostatic hyperplasia manufactured by
Boehringer Ingelheim for the US and Canadian

markets shares the same brand name, Flomax
(morniflumate), that is used for pain, fever, or
inflammation as manufactured by Chiesi in Italy.
The antidepressant, Norpramin (desipramine),
produced by Aventis, is the anti-ulcer drug,
omeprazole (Norpramin) in Spain where it is
produced by CEPA. Sominex (diphenhydramine)
is promethazine in the United Kingdom; Vivelle
(estradiol) is ethinylestradiol, norgestimate by
Janssen-Cilag in Austria; Fiorinal contains
aspirin, butalbital, and caffeine but in Australia it
is paracetamol, codeine, and doxylamine.2
Foreign over-the-counter (OTC) brand
products may not be the same and may even have
the same brand name as a prescription product.
Cartia is an enteric coated aspirin product in
Israel, Australia, New Zealand, and Hong Kong.
In the US Cartia XT is extended release diltiazem.
US and Canadian OTC brand name extensions
create confusion due to the practice of reusing
OTC brand names for products with different
ingredients. Unisom in the US and Canada
contains doxylamine whereas Unisom SleepGels
contain diphenhydramine as marketed in both
countries.3
Currently there is no international body that
oversees brand name selection by pharmaceutical
manufacturers. The World Health Organization
has established general principles for devising
international
nonproprietary
names
for
They
also
maintain
pharmaceuticals.5
international monographs for pharmaceutical
substances.6 Proprietary name regulation will be
another major area for international observation,
control, and safety.
As noted by the ISMP, brand name differences
in foreign countries are one problem but so are
differences in dosage forms for the same generic
with their suffix listings. Drug dosage form
release characteristics, as represented by the brand
name suffix (XR, LA, XL, etc.) vary and can cause
patients to receive too much or too little of an outMore. . .
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of-country obtained medication. There is no
international nomenclature standard for release
characteristics.2
Look-alike and sound-alike brand name drug
lists are readily available in the US and Canada.
There is a great potential for patient safety
problems with foreign look-alike and sound-alike
brand names. Unisomnia in Great Britain is a
benzodiazepine, nitrazepam, used for insomnia.4
Nitrazepam’s brand name is Sonotrat in Brazil.
When written, it might be confused with Sonata
(zaleplon) also used for insomnia in the US and
Canada.4 Trexall is methotrexate in the US but
Trexan is naltrexone in Italy. Amyben, available
in the United Kingdom, is amiodarone. If this
were dispensed for the sedative, Ambien
(zolpidem) a significant adverse event could
occur.2 Trental is pentoxifylline in the US and
Canada.
Trentadil is bamifylline, a
bronchodilator, in France.4 The antipsychotic,
Prolixin, (fluphenazine) might look like and
sound like Prolixan (azapropazone), a nonsteroidal anti-inflammatory agent, used in some
European countries.4 International cautionary lists
do not exist at this time for brand names.

Advice
Patients who are traveling abroad should have
a complete list of their medications with both
brand and generic names including the brand
dosage form, dosage, use frequency, and purpose
of use. They should bring a sufficient supply of
their medications in labeled bottles or packages
with allowances for unexpected travel delays.
Should they need a refill, remind them to actively
check the generic name, dosage form, and
strength to confirm a match. If they are ordering
medication from an internet pharmacy they should
ask their prescriber to clearly write this same
information on the prescription.
Healthcare professionals needing information
on imported or foreign country medications may
find references such as the Micromedex products,
Martindale: The Complete Drug Reference and
Index Nominum International Drug Directory,
helpful. Lexi-Comp’s Lexi-Drugs International is
an additional source.
Drug information or poison control centers in
the US can be contacted for help. In the US the
national toll-free number is: 800-222-1222. The
American Association of Poison Control Centers

maintains a complete list of poison control
centers. They include centers in Canada, New
Zealand, Australia, and Puerto Rico.
Their
website
can
be
found
at:
http://www.aapcc.org/findyour.htm. In Canada, a
list of poison control centers can be found at:
http://www.capcc.com or http://www.napra.org/
practice/Toolkits/Toolkit6/poison_control.html.
Be aware that every center may not be able to
immediately answer a question, unless it is of an
emergency basis.
Encourage reporting of potential product
problems or actual occurrences. To report product
problems in the US, call the FDA MEDWATCH
program at 1-800-FDA-1088. The MEDWATCH
program is also available on-line at
www.fda.gov/medwatch. Or report to the USP
Medication Errors Reporting Program in
cooperation with the Institute for Safe Medication
Practices
at
1-800-23-ERROR
or
at
www.usp.org/patientSafety/reporting/mer.html.
In Canada, call the Canadian Adverse Drug
Reaction Monitoring Program at 1-866-234-2345.
The Canadian adverse reaction reporting form can
be found at: http://www.hc-sc.gc.ca/hpfbdgpsa/tpd-dpt/adverse_e.pdf.
It should be
completed and faxed to 1-866-678-6789. You can
also contact the Institute for Safe Medication
Practices (ISMP) by calling 215-947-7797 or
reporting on-line at www.ismp.org/Pages/
communications.asp.

Users of this document are cautioned to use their own
professional judgment and consult any other necessary
or appropriate sources prior to making clinical
judgments based on the content of this document. Our
editors have researched the information with input
from experts, government agencies, and national
organizations. Information and Internet links in this
article were current as of the date of publication.
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